OncoMatch/Clinical Trials/NCT06462248
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Is NCT06462248 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CUCART19 for lymphoma, nonhodgkin.
Treatment: CUCART19 — CAR-T therapy is now available as a commercial product for treatment of relapsed /refractory acute lymphoblastic leukaemia and B-lymphoma. There is limited access to this new treatment as the product is very expensive. It is imperative to develop cost effective, closed circuit manufacturing systems for CAR-T cells to make CAR-T cells a point-of care production option. Hong Kong Institute of Biotechnology has established a certified GMP facility and utilize the Prodigy system to manufacture CAR-T cells for clinical application. Prince of Wales Hospital and Hong Kong Children's Hospital will conduct the phase II clinical trial to confirm the efficacy and safety of local manufactured CAR-T cell product.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
Required: CD19 positive
Performance status
ECOG/LANSKY 0–2
Prior therapy
Must have received: intensive systemic therapy
Lab requirements
Kidney function
Creatinine clearance <50 mL/min/1.73 m2
Liver function
serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukaemic liver infiltration in the estimation of the investigator
Cardiac function
Fractional shortening <28% or left ventricular ejection fraction <45% by echocardiography
Pulmonary function: Grade 1 dyspnea and pulse oxygenation > 91% on room air; Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <45% by echocardiography. Renal function: Creatinine clearance <50 mL/min/1.73 m2. Liver function: Patients with a serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukaemic liver infiltration in the estimation of the investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify